July 6th 2022
Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.
June 4th 2022
Raajit K. Rampal, MD, PhD, discusses the investigation of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.
October 12th 2021
Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.
September 2nd 2021
Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.
August 3rd 2021
Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.
July 22nd 2021
Raajit K. Rampal, MD, PhD, discusses considerations for selecting among the JAK inhibitors ruxolitinib and fedratinib in the treatment of patients with myelofibrosis.
December 8th 2020
Raajit K. Rampal, MD, PhD, discusses the evolution of prognostic models in essential thrombocythemia.
October 13th 2020
Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.
September 28th 2020
Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.
September 24th 2020
Raajit K. Rampal, MD, PhD, discusses the evolving understanding of genetic alterations in myeloproliferative neoplasms.
February 22nd 2020
Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.
January 24th 2020
Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.
January 15th 2020
Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.
January 8th 2020
Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.